BIOATLA, INC. (BCAB) Current Ratio
- Current ratio · latest quarter: Value 0.20×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.20× | Current assets / current liabilities. $4.26M ÷ $21.02M ≈ 0.20× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 4.26M USD | Assets, Current |
| Current obligations | 21.02M USD | Liabilities, Current |
| Cash and equivalents | 1.54M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 2.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 12.71M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.26M | $21.02M | $1.54M | (m) | $2.00M | (m) | $12.71M | (m) | 0.20× |
| 2026-03-31 | $3.09M | $20.69M | $1.96M | (m) | (m) | (m) | $12.12M | (m) | 0.15× |
| 2025-12-31 | $8.01M | $21.92M | $7.12M | (m) | $0.00 | (m) | $8.19M | (m) | 0.37× |
| 2025-09-30 | $9.67M | $17.98M | $8.32M | (m) | (m) | (m) | $5.85M | (m) | 0.54× |
| 2025-06-30 | $20.61M | $16.60M | $18.21M | (m) | (m) | (m) | $4.64M | (m) | 1.24× |
| 2025-03-31 | $37.54M | $16.01M | $32.36M | (m) | (m) | (m) | $4.70M | (m) | 2.35× |
| 2024-12-31 | $51.23M | $14.54M | $49.05M | (m) | (m) | (m) | $1.90M | (m) | 3.52× |
| 2024-09-30 | $60.57M | $19.46M | $56.52M | (m) | (m) | (m) | $2.93M | (m) | 3.11× |
| 2024-06-30 | $66.49M | $17.46M | $61.66M | (m) | (m) | (m) | $1.36M | (m) | 3.81× |
| 2024-03-31 | $86.42M | $19.26M | $80.63M | (m) | (m) | (m) | $3.45M | (m) | 4.49× |
| 2023-12-31 | $116.41M | $28.34M | $111.47M | (m) | (m) | (m) | $3.82M | (m) | 4.11× |
| 2023-09-30 | $147.51M | $35.60M | $141.28M | (m) | (m) | (m) | $6.29M | (m) | 4.14× |
| 2023-06-30 | $175.31M | $33.65M | $168.69M | (m) | (m) | (m) | $2.97M | (m) | 5.21× |
| 2023-03-31 | $199.72M | $26.26M | $192.69M | (m) | (m) | (m) | $8.05M | (m) | 7.61× |
| 2022-12-31 | $220.43M | $23.13M | $215.51M | (m) | (m) | (m) | $4.23M | (m) | 9.53× |
| 2022-09-30 | $183.31M | $23.82M | $178.12M | (m) | (m) | (m) | $3.70M | (m) | 7.69× |
| 2022-06-30 | $207.20M | $25.51M | $202.29M | (m) | (m) | (m) | $4.82M | (m) | 8.12× |
| 2022-03-31 | $224.02M | $17.19M | $219.43M | (m) | (m) | (m) | $1.20M | (m) | 13.03× |
| 2021-12-31 | $247.29M | $19.81M | $244.98M | (m) | (m) | (m) | $1.18M | (m) | 12.48× |
| 2021-09-30 | $273.52M | $45.23M | $269.93M | (m) | (m) | (m) | $1.55M | (m) | 6.05× |
| 2021-06-30 | $212.33M | $36.16M | $207.61M | (m) | (m) | (m) | $1.28M | (m) | 5.87× |
| 2021-03-31 | $224.58M | $30.53M | $221.20M | (m) | (m) | (m) | $2.50M | (m) | 7.36× |
| 2020-12-31 | $240.68M | $32.26M | $238.60M | (m) | (m) | (m) | $2.46M | (m) | 7.46× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |